Iovance Biotherapeutics Reports 45% Revenue Growth to $71.4 Million in Q1 2026

Iovance Biotherapeutics, Inc. reported a significant increase in financial performance for the first quarter of 2026, with total revenue reaching $71.4 million, a 45% increase from $49.3 million in the same period of 2025. This growth was primarily driven by a 38% rise in sales of its flagship product, Amtagvi® (lifileucel), which generated $60.2 million, and a 95% increase in Proleukin® (aldesleukin) sales, which contributed $11.2 million. The company’s net loss for the quarter was $79.0 million, a 32% reduction from the $116.2 million loss reported in the prior year, reflecting improved operational efficiency and increased product sales.

In terms of operational changes, Iovance has made strategic decisions to enhance its market position. The company completed the acquisition of worldwide rights to Proleukin® in May 2023, which has begun to positively impact revenue. Additionally, Iovance is focusing on expanding its commercial infrastructure for Amtagvi®, which is now approved for use in the U.S. and Canada. The company plans to launch Amtagvi® in additional markets, with potential approvals pending in Australia and Switzerland in the coming years.

Iovance's operational metrics indicate a strong trajectory, with cash and cash equivalents totaling $196.5 million as of March 31, 2026, up from $163.1 million at the end of 2025. The company has also streamlined its workforce by approximately 19% as part of a restructuring plan aimed at reducing costs and optimizing operations. This restructuring is expected to enhance the company's ability to fund ongoing clinical programs and support the commercial launch of Amtagvi®.

The company’s research and development expenses decreased by 18% to $62.5 million, down from $76.0 million in the previous year, primarily due to reduced clinical trial costs and lower stock-based compensation expenses. Selling, general, and administrative expenses also fell by 11% to $38.9 million, reflecting a decrease in stock-based compensation and other operational costs. These reductions in expenses, combined with increased revenues, have contributed to the narrowing of the net loss.

Looking ahead, Iovance anticipates continued investment in its clinical programs and the commercialization of its products. The company expects to incur significant expenses as it supports the ongoing launch of Amtagvi® and funds its clinical trials, including those for non-small cell lung cancer and other solid tumor indications. Despite the current losses, Iovance believes it has sufficient capital to fund its operations for at least the next twelve months, bolstered by its recent revenue growth and strategic initiatives.